TGM-010
Neurological Disorders (Broad-Spectrum)
PreclinicalActive
Key Facts
About GenrAb
GenrAb is a private, preclinical-stage biotech leveraging its proprietary Antibody Gene Signature (AGS) platform to discover fully human, neuroprotective monoclonal antibodies from patients with neurological disorders. The company's lead candidate, TGM-010, targets a conserved neurodegenerative pathway and has shown efficacy in reducing disability in preclinical models, with a pipeline of over 400 identified mAbs. GenrAb is addressing a significant unmet need in neurology, as there are currently no approved disease-modifying neuroprotective therapies on the market, positioning itself to potentially treat a range of conditions like ALS, Alzheimer's, Parkinson's, and Multiple Sclerosis.
View full company profile